Prevalence of dysphagia in patients with multiple sclerosis; a systematic review and meta-analysis

Mirmosayyeb, Omid; Ebrahimi, Narges; Shekarian, Arman; Bagherieh, Sara; Afshari-Safavi, Alireza; Shaygannejad, Vahid; Barzegar, Mahdi

doi:10.1101/2021.06.07.21258473

Cited by 4 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Available data regarding patients with MS, although highly heterogeneous, show an increased prevalence and incidence of seizures compared with the general population. An older systematic review estimated the prevalence of seizures at 3.09% and the incidence at 2.28% for patients with MS (28), being in line with more recent figures which show a pooled prevalence of 2% for seizures and 3% for epilepsy among patients with MS (29). Similar data were extracted from other studies, but with greater inter-study variability.…”

Section: Epidemiological Data Revealing a Significant Association Bet...supporting

confidence: 80%

“…Calabrese et al (94) report that intracortical lesions are five times more common in patients with RRMS with concomitant epileptic seizures. Another study shows that cortical and juxtacortical lesions are independent predictors of seizures, epilepsy being also related to brain lesion load and cerebral parenchyma atrophy (29). The use of newer imaging techniques for diagnosis and follow-up [such as double inversion recovery (DIR), and high-resolution (3-7 Tesla) MRI sequences] has improved the early detection of cortical lesions (94).…”

Section: The Role Of Imagistic Techniques In Studying the Ms-epilepsy...mentioning

confidence: 99%

See 1 more Smart Citation

Seizures and multiple sclerosis‑more than an epidemiological association (Review)

Antal

Schreiner

Crihan³

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

In order to increase the quality of life of patients with epilepsy, it is essential to develop tools that facilitate early disease diagnosis and encourage the use of individualized therapies. The association between seizures and other neurological pathologies is well known but incompletely explained, with multiple sclerosis (MS)-seizures correlation being a relevant example. In this context, the present review aimed to highlight the most important facts related to the association between the heterogeneous group of epileptic pathology and MS, in order to provide initial directions for establishing a diagnostic and therapeutic protocol. The first part reviewed the most relevant epidemiological and clinical data on seizures; MS association. Subsequently, it highlighted the most common and actually accepted pathophysiological mechanisms that try to explain the association between the two pathologies. Finally, the importance of paraclinical investigations and the optimal choice of antiseizure-based therapies with respect to seizures associated with MS are presented, also revealing several directions that should be explored in the near future. Contents 1. Introduction 2. Methodology and method 3. Epidemiological data revealing a significant association between MS and seizures 4. Relevant aspects of seizures in patients with MS 5. Pathophysiological mechanisms (incompletely) explaining the MS-epilepsy association 6. The role of imagistic techniques in studying the MS-epilepsy association 7. Neurophysiology in patients with MS with epilepsy-in search of specific patterns 8. Individualized ASMs treatment and prognosis in patients with MS with epilepsy 9. Conclusions

show abstract

Section: Epidemiological Data Revealing a Significant Association Bet...supporting

confidence: 80%

Section: The Role Of Imagistic Techniques In Studying the Ms-epilepsy...mentioning

confidence: 99%

Seizures and multiple sclerosis‑more than an epidemiological association (Review)

Antal

Schreiner

Crihan³

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…10,11 On the other hand, seizures are rare in MS; a pooled analysis of 39 studies found the prevalence of seizures and epilepsy in MS patients to be 2% and 3%, respectively. 12 As with MS, gliomas may cause focal neurologic deficits depending on the size and location of the tumor and on the amount of vasogenic edema. Focal deficits in gliomas are typically initially subtle, subacute to chronic and progressive, though they may present more acutely in rapidly growing tumors.…”

Section: Discussionmentioning

confidence: 99%

Glioblastoma in Patients With Multiple Sclerosis

Berkman

Nakhate

Castro

2022

The Neurohospitalist

View full text Add to dashboard Cite

Background Although rare, the co-occurrence of multiple sclerosis (MS) and glioma poses unique challenges in terms of diagnosis and management for both neurologists and neuro-oncologists. Methods Here we report on a single-center cohort of four patients with a diagnosis of multiple sclerosis who developed gliomas. Results Our cohort reflects the epidemiology of glioma in terms of the relative frequency of IDH-wildtype and IDH-mutant cases. The patients in 3 out of the 4 cases presented did not develop their tumors in areas of pre-existing demyelinating lesions. Conclusions We did not find evidence to support the hypothesis that chronic gliosis from demyelinating plaques may serve as a substrate for secondary induction of a glial neoplasm. In our Discussion, we provide recommendations for distinguishing neoplastic from demyelinating lesions, review the evidence for demyelination as a risk factor for gliomagenesis, and highlight important considerations for the concurrent management of glioma and MS.

show abstract

“…Findings on the prevalence and incidence of seizures/epilepsy in MS vary by region and are currently based on data from Europe, North and South America, and Asia (Figure 1). The most recent meta‐analysis of 39 papers in 2021 has shown that the prevalence of seizures in MS is approximately 2%, 29 which is much lower than that in AE (69.9%) 30 . The prevalence of seizures/epilepsy increases with the course of the MS and the number of lesions 31 .…”

Section: Epidemiologymentioning

confidence: 99%

Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody‐associated disease

Zheng

Cai

et al. 2022

Epilepsia

View full text Add to dashboard Cite

Seizure is one of the manifestations of central nervous system inflammatory demyelinating diseases, which mainly include multiple sclerosis (MS), aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4‐NMOSD), and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD). Acute symptomatic seizures secondary to MS/AQP4‐NMOSD/MOGAD occur in the acute phase of the diseases, and are more frequent in MOGAD. In contrast, recurrent nonprovoked seizures, mainly attributed to autoimmune‐associated epilepsy, occur in the nonacute phase of the diseases. Seizures in MS/AQP4‐NMOSD/MOGAD mostly have a focal onset. MS patients with concomitant systemic infections, earlier onset, and greater disease activity are more likely to have seizures, whereas factors such as greater MS severity, the presence of status epilepticus, and cortical damage indicate a greater risk of developing epilepsy. In MOGAD, cerebral cortical encephalitis and acute disseminated encephalomyelitis (ADEM)‐like phenotypes (predominately ADEM and multiphasic disseminated encephalomyelitis) indicate a greater seizure risk. Multiple relapses with ADEM‐like phenotypes predict epilepsy in pediatrics with MOGAD. Pathophysiologically, acute symptomatic seizures in MS are associated with neuronal hyperexcitability secondary to inflammation and demyelination. Chronic epilepsy in MS is largely due to gliosis, neuronal dysfunction, and synaptic abnormalities. The mainstay of treatment for seizures secondary to MS/AQP4‐NMOSD/MOGAD consists of immunotherapy along with antiseizure medications. This critical review discusses the most‐updated evidence on epidemiology, clinical correlates, and inflammatory mechanisms underlying seizures and epilepsy in MS/AQP4‐NMOSD/MOGAD. Treatment cautions including drug‐drug interactions and the impact of treatments on the diseases are outlined. We also highlight pitfalls and challenges in managing such patients and future research perspectives to address unsolved questions.

show abstract

Prevalence of dysphagia in patients with multiple sclerosis; a systematic review and meta-analysis

Cited by 4 publications

References 31 publications

Seizures and multiple sclerosis‑more than an epidemiological association (Review)

Seizures and multiple sclerosis‑more than an epidemiological association (Review)

Glioblastoma in Patients With Multiple Sclerosis

Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody‐associated disease

Contact Info

Product

Resources

About